REMS And Generics: GPhA Needs Legislation, Continues Education
Executive Summary
GPhA says congressional action is only remedy after study estimates $5.4 billion in potential savings is lost annually because of brand manufacturers using REMS to prevent generic competition.
You may also be interested in...
Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.
Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
Although panelists expressed concerns about REMS misuse as barrier to competition, Republicans did not appear interested in the topic.